UTRF licenses cell line commercial rights to CytoSen Therapeutics

UTRF NewThe University of Tennessee’s Research Foundation recently executed a license granting CytoSen Therapeutics Inc.  the commercial rights to use the K-562 cell lines to produce an innovative natural killer cell therapy that harnesses the power of a person’s own immune cells to help fight cancer. Read more here.

Stay connected with us on Twitter and LinkedIn. Article ideas and other suggestions should be sent to tballard@pyapc.com. Include the name and contact information (phone and email) for follow-up.